Progressive Dysmorphism of Retinal Pigment Epithelium in Age-Related Macular Degeneration Investigated by Fluorescence Lifetime Imaging

Martin Hammer,1,3 Juliane Jakob-Girbig,1 Linda Schwanengel,1 Christine A. Curcio,2 Somar Hasan,1 Daniel Meller,1 and Rowena Schultz1

1Department of Ophthalmology, University Hospital Jena, Jena, Germany
2Department of Ophthalmology and Visual Sciences, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States
3Center for Medical Optics and Photonics, Univ. of Jena, Jena, Germany

Correspondence: Martin Hammer, University Hospital Jena, Department of Ophthalmology, Am Klinikum 1, 07747 Jena, Germany; martin.hammer@med.uni-jena.de.

Received: April 21, 2021
Accepted: August 9, 2021
Published: September 7, 2021


PURPOSE. The purpose of this study was to observe changes of the retinal pigment epithelium (RPE) on the transition from dysmophia to atrophy in age-related macular degeneration (AMD) by fluorescence lifetime imaging ophthalmoscopy (FLIO).

METHODS. Multimodal imaging including color fundus photography (CFP), optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging, and FLIO was performed in 40 eyes of 37 patients with intermediate AMD and no evidence for geographic atrophy or macular neovascularisation (mean age = 74.2 ± 7.0 years). Twenty-three eyes were followed for 28.3 ± 18.3 months. Seven eyes had a second follow-up after 46.6 ± 9.0 months. Thickened RPE on OCT, hyperpigmentation on CFP, hyper-reflective foci (HRF) on OCT, attributed to single or clustered intraretinal RPE, were identified. Fluorescence lifetimes in two spectral channels (short-wavelength spectral channel [SSC] = 500–560 nm, long-wavelength spectral channel [LSC] = 560–720 nm) as well as emission spectrum intensity ratio (ESIR) of the lesions were measured by FLIO.

RESULTS. As hyperpigmented areas form and RPE migrates into the retina, FAF lifetimes lengthen and ESRI of RPE cells increase. Thickened RPE showed lifetimes of 256 ± 49 ps (SSC) and 336 ± 35 ps (LSC) and an ESIR of 0.552 ± 0.079. For hyperpigmentation, these values were 317 ± 68 ps (p < 0.001), 377 ± 56 ps (P < 0.001), and 0.609 ± 0.081 (P = 0.001), respectively, and for HRF 337 ± 79 ps (P < 0.001), 414 ± 50 ps (P < 0.001), and 0.654 ± 0.075 (P < 0.001).

CONCLUSIONS. In the process of RPE degeneration, comprising different steps of dysmorphism, hyperpigmentation, and migration, lengthening of FAF lifetimes and a hypsochromic shift of emission spectra can be observed by FLIO. Thus, FLIO might provide early biomarkers for AMD progression and contribute to our understanding of RPE pathology.

Keywords: age-related macular degeneration (AMD), retinal pigment epithelium (RPE), fundus autofluorescence (FAF), fluorescence lifetime, fluorescence spectra, atrophy, migration

Although age-related macular degeneration (AMD) is a multifactorial disease, the end stage of non-neovascular AMD includes atrophy of the retinal pigment epithelium (RPE). This is seen as geographic atrophy (GA) in color fundus photography (CFP) and is incorporated into complete RPE and outer retinal atrophy (cRORA) in optical coherence tomography (OCT). Consequently, RPE alteration, seen in CFP or OCT, is a risk factor for disease progression.2–5 Histopathology as well as clinical imaging revealed multiple morphologically distinct pathways to atrophy, mainly intraretinal migration and shedding of organelles into underlying basal laminar deposits (BLamDs).6–7 The best studied pathway involves RPE cells detaching from the RPE basal lamina (BL) and subsequently migrating into the retina, where they appear as hyper-reflective foci (HRF) in OCT.8–10 In a post hoc analysis of a standardized imaging dataset from a prospective clinical trial, HRF were found to confer risk for RPE atrophy with a 2 year odds ratio of 5.2.11

Due to its accumulation of lipofuscin and melanolipofuscin, RPE contributes the strongest fluorescence emission in fundus autofluorescence imaging (FAF).12–17 High resolution microscopy revealed distinct autofluorescent organelles18 and spectrally resolved microscopy uncovered emission spectra specific for RPE fluorophores and for sub-RPE tissues.19 Hyperautofluorescence in FAF was studied as a marker of AMD progression and GA growth clinically20–24.
as well as in histopathology. Furthermore, hyperpigmentation in CFP is associated with hyperautofluorescence in FAF.

Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a technique extending FAF imaging to the measurement of fluorescence lifetimes. Measuring the average time (in the order of picoseconds) a fluorescent molecule remains in an excited electronic state after excitation by a short laser pulse, fluorescence lifetime imaging characterizes the molecule, and its embedding matrix. In clinical FLIO imaging, however, a variety of fluorophores can contribute to the signal. As it is impossible to resolve all molecules from the fluorescence decay signal, these measurements cannot directly address single molecules but characterize the overall state of tissue, comprising all retinal layers, at each pixel in the image. A general prolongation of FAF lifetimes as well as further prolongation with disease progression was found in AMD. Specifically, hyperpigmented areas in CFP exhibited longer FAF lifetimes and shorter emission wavelengths than the surrounding less affected areas in the fundus.

In the current retrospective study, we used multimodal imaging to investigate the natural history of drusen-associated RPE dysmorphism as defined in CFP and OCT, with the expectation that these cells are abnormal and thus would exhibit distinctive signals in FAF and FLIO. In this study, dysmorphic RPE atop drusenoid RPE detachment (PED), hyperpigmentation, and migrated RPE were examined separately in order to observe FAF lifetime changes and identify AMD progression markers seen in FLIO. A second pathway to RPE atrophy, related to subretinal drusenoid deposits, was not considered here.

**Methods**

**Subjects and Procedures**

In this retrospective study, patients with AMD, which was non-neovascular at the time of inclusion, seen at the University Hospital Jena, Department of Ophthalmology, between April 2014 and January 2021 were enrolled. Exclusion criteria were the presence of GA or macular neovascularization at the baseline visit, other retinal retina-involving pathologies, such as diabetic retinopathy, glaucoma, hypertensive retinopathy, retinal vascular occlusion, central serous chorioretinopathy, macular telangiectasia 2, Stargardt disease, retinitis pigmentosa, macular holes, and retinal detachment. Patients were also excluded in case of mature cataract preventing high quality fundus imaging.

The study was approved by the ethics committee of the University Hospital Jena and adhered to the tenets of the Declaration of Helsinki. All participants gave written informed consent prior to study inclusion and underwent a full ophthalmologic examination including best corrected visual acuity, OCT (Cirrus-OCT; Carl-Zeiss Meditec AG, Jena, Germany) and CFP (Visucam; Carl-Zeiss Meditec AG, Jena, Germany). Pupils were dilated using tropicamide (Mydri- Hickl GmbH, Berlin, Germany) and CFP (Visucam; Carl-Zeiss Meditec AG, Jena, Germany). Pupils were dilated using tropicamide (Mydri- Hickl GmbH, Berlin, Germany) and CFP (Visucam; Carl-Zeiss Meditec AG, Jena, Germany). Pupils were dilated using tropicamide (Mydri- Hickl GmbH, Berlin, Germany) and CFP (Visucam; Carl-Zeiss Meditec AG, Jena, Germany).

The resulting image is color-coded, depicting short lifetimes in red and long lifetimes in blue color. In addition, the ratio of photon counts (autofluorescence intensity) in SSC and LSC was calculated per pixel, which is denoted as the emission spectrum intensity ratio (ESIR; previously called spectral ratio).

The software FLIMX, which is documented and freely available for download under an open-source Berkeley Software Distribution (BSD) license (http://www.flimx.de), was used for the manual selection of lesions as regions of interest (ROI). As there was no automatic image registration available for CFP, OCT, and FLIO, the registration was done manually to make sure that we address the same lesions in all imaging modalities. Mean FAF lifetimes and ESIR per pixel were averaged over all pixels of the ROI as well as the environment of the ROI, a 105-μm wide area, which was 35 μm distant to the ROI.

From previous literature, several imaging indicators of dysmorphic RPE and its underlying BL can be assembled for use in reference to FLIO. The RPE and the RPE-BL are best thought of as separate from an underlying three-layer Bruch’s membrane. In OCT, a thickening of the RPE-BL band can be observed especially over drusen and drusenoid pigment epithelial detachment (PED). Thickening precedes the appearance of HRF directly above in the overlying retina but thickening may or may not still be present if and when HRF appears. In non-neovascular AMD, HRF have been directly correlated with nucleated cells containing RPE organelles at the same qualitative abundance as cells in the intact RPE layer; in neovascular AMD HRF also includes lipid-filled cells not resembling RPE. Hyperpigmentation in CFP is a nonspecific term that encompasses several possibilities, including proliferation (cell division) of RPE cells, rounding or stacking individual RPE cells, and increased size or concentration of melanin-containing organelles (melanosomes and melanolipofuscin), all of which may increase pathlength of light through light-absorbing melanin protein. Thus, hyperpigmentation in CFP can be associated with thickened RPE-BL or HRF in OCT. Thickening of RPE-BL, however, also can occur without hyperpigmentation.

Two reviewers (authors J.G. and M.H.), masked to the lifetimes, marked hyperautofluorescent areas in FAF (SSC or LSC) and graded them according to OCT and CFP features: OCT was checked for the presence of drusen or drusenoid PED (smallest diameter > 350 μm).
thickening of the RPE-BL band, and the presence or absence of HRF anterior to the ellipsoid zone. CFP was checked for the presence or absence of hyperpigmentation. This way, we found three lesion entities consistent with the histologic findings described above: (i) a thickened RPE-BL band atop drusenoid PED with no hyperpigmentation in CFP, (ii) hyperpigmentation associated with thickened RPE-BL but no HRF, and (iii) HRF independent from the thickness of the underlying RPE-BL which was hyperpigmented.

Lesions were excluded if the reviewers graded differently. To exclude hyperautofluorescent drusen from the analysis, areas that were not clearly thickened in OCT and hyperpigmented in CFP were excluded. In addition, areas with incipient atrophy were excluded. Lesions in the fovea (central 400 μm in diameter) were excluded as well because of FLIO signal from macular xanthophyll pigment. Acquired vitelliform lesions were also excluded. Grading was done independently for each patient visit with reference to the prior visit.

Statistics

FAL lifetimes and ESIR of lesions and their environment were compared by paired t-test. Data for groups of lesions (thickened RPE-BL, hyperpigmentation, and HRF) was compared using ANOVA with post hoc Bonferroni test compensating for multiple testing. For this test, each lesion entity was included at baseline. The correlation of the follow-up time with the changes of lifetimes and ESIR from baseline to follow-up was tested.

RESULTS

Forty eyes of 37 patients (mean age = 74.2±7.0 years) were included. Twenty-four eyes (60%) were pseudophakic. Thirty eyes of 25 patients had a follow-up of 28.3±9.0 months after baseline. Study patient demographics and lesion fate are given in Table 1. At baseline, we found 58 areas of thickened RPE atop PED on OCT; 38 areas of hyperpigmentation on CFP without PED on OCT; and 126 HRF. We observed the disappearance of 9 PEDs (6 at first and 3 at second follow-up) and 15 HRF at first follow-up. Four spots of hyperpigmentation turned to HRF at follow-up. Over follow-up, we found 11 newly appearing PEDs, 7 new spots of hyperpigmentation (3 over drusen and 4 over PED), and 28 new HRF (6 over drusen and 22 over recent or collapsed PED). At first follow-up, 5 out of 30 eyes had a central cRORA, one a paracentral cRORA, one an outer retinal atrophy, and 3 a macular neovascularization (MNV). At the second follow-up, we found one more central and one more parafocal (inner ring of the ERTDRS-grid) cRORA as well as one more MNV.

Hyperpigmentation and HRF have strong FAL with long lifetimes whereas thickened RPE on top of PED shows diffuse hyperfluorescence with short lifetimes. A typical example is shown in Fig. 1. This patient was imaged at baseline and at two follow-up visits 24 and 52 months later. The natural history of PED is exemplified in two OCT sections. Superior to the macula we see a PED with hyperpigmentation at baseline. Its growth over 24 months is associated with the appearance of HRF (see Fig 1c) showing strong focal hyperfluorescence with long lifetimes (at white arrowheads). At month 52, the PED is partly collapsed and partly denuded of RPE. Atrophy is seen by the penetration of laser light into the choroid in OCT (see Fig. 1f) and a hypofluorescence with long lifetimes in LSC (see Figs. 1p, 1v). Interestingly, this incipient atrophy does not show hypofluorescence but already long lifetimes in SSC. Whereas we hardly see RPE attached to the still-elevated persistent BlLamD (red arrowhead in Fig. 1f), HRF remaining in the retina (see Fig. 1f), and can contribute to the long lifetime fluorescence. Inferior to the macula, we see also growth of PED, which becomes hyperautofluorescent at month 24 (see Figs. II, 1o, black arrowhead). In contrast to hyperpigmentation and HRF, PED have short FAL lifetimes. At month 52, we found these PEDs collapsed leaving large HRF with long lifetimes again (black arrowheads in Figs. 1c, 1i, 1m, 1p, 1s, 1v). Finally, at month 52, we see one very small HRF (purple arrowhead in Figs. 1c, 1j, 1m, 1p, 1s, 1v), which is hardly discernible in CFP. FLIO, however, clearly shows that this lesion has a long FAL lifetime.

Whereas intraretinal HRF (i.e. internal to the ellipsoid zone) always show long lifetimes, in hyperpigmentation associated with focal thickening of the RPE-BL band we found a transition from short to long lifetimes. Figure 2 shows an example (arrowheads point to hyperpigmented spots with various FAL lifetimes). At hyperpigmentation (Fig. 3, arrowhead), we observed a change from hyperfluorescence with initially short lifetime to long lifetime upon the appearance of HRF with no PED 35 months later. However, long lifetimes are also seen before the advent of atrophy in the absence of HRF. Fig. 4 shows a patient at baseline and 21 months later. The white arrowheads point to thickened RPE showing short lifetime, whereas long lifetimes also were

Table 1. Patient Demographics and Fate of RPE Lesions

<table>
<thead>
<tr>
<th>Patient Information</th>
<th>Baseline</th>
<th>Follow Up 1</th>
<th>Follow Up 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (patients)</td>
<td>37 (100%)</td>
<td>25 (68%)</td>
<td>11 (30%)</td>
</tr>
<tr>
<td>Female</td>
<td>23 (62%)</td>
<td>14 (56%)</td>
<td>5 (45%)</td>
</tr>
<tr>
<td>Male</td>
<td>14 (38%)</td>
<td>11 (44%)</td>
<td>6 (55%)</td>
</tr>
<tr>
<td>Age (years, mean ± SD)</td>
<td>74.2 ± 7.0</td>
<td>74.0 ± 6.3</td>
<td>70.8 ± 4.5</td>
</tr>
<tr>
<td>N (eyes)</td>
<td>40 (100%)</td>
<td>30 (30%)</td>
<td>12 (30%)</td>
</tr>
<tr>
<td>Eyes progressed to MNV</td>
<td>3 (10%)</td>
<td>4 (33%)</td>
<td></td>
</tr>
<tr>
<td>Eyes progressed to atrophy</td>
<td>6 (20%)</td>
<td>5 (67%)</td>
<td></td>
</tr>
<tr>
<td>RPE lesions</td>
<td>N</td>
<td>gain(+)loss(−)</td>
<td>gain(+)loss(−)</td>
</tr>
<tr>
<td>Thicken at PED</td>
<td>58 (100%)</td>
<td>+5 (9%)/−6 (10%)</td>
<td>+11 (19%)/−9 (16%)</td>
</tr>
<tr>
<td>Hyperpigmentation</td>
<td>38 (100%)</td>
<td>+2 (5%)/−4 (11%)</td>
<td>+7 (18%)/−4 (11%)</td>
</tr>
<tr>
<td>HRF</td>
<td>126 (100%)</td>
<td>+15 (12%)/−15 (12%)</td>
<td>+28 (22%)/−15 (12%)</td>
</tr>
</tbody>
</table>

Percentages of number of eyes at follow ups refer to that at baseline. Percentages of female subjects, male subjects, and AMD progression refer to the number of subjects at the respective visit. Percentages of gain and loss of lesions refer to the number at baseline.
FIGURE 1. Natural history of a PED with RPE migration. (A–C) CFP, (D–J) OCT, (K–M) FAF SSC, (N–P) FAF LSC, (Q–S) FLIO SSC, and (T–V) FLIO LSC of a 64-year-old patient at baseline (left column: A, D, G, K, N, Q, and T), 24 months (middle column: B, E, H, I, O, R, and U) and 52 months follow-up (right column: C, F, I, J, M, P, S, and T). Green lines in A to C show the localization of OCT scans. White arrowheads: HRF that correspond to hyperpigmentation on CFP. Red arrowhead: BLamD that persists after death or migration of RPE. Black arrowheads: Growth of PED at months 24 leaving migrated RPE at month 52. Purple arrowhead: Migrated RPE with HRF, no history of PED at this point, but clearly prolonged lifetimes in FLIO.
Figure 2. RPE cells detaching from the RPE layer. (A) CFP, (B, C) OCT (scans were tilted to display them horizontally, thus shadows of the hyperpigmentations are obliquely oriented), (D) FAF SSC, (E) FAF LSC, (F) FLIO SSC, and (G) FLIO LSC of an 81-year-old patient. White arrowheads show corresponding hyperpigmentation A, activated RPE cells B and C, iso- and hyper-FAF D and E, and lengthening lifetimes F and G.
FIGURE 3. Change of FAF lifetime of RPE in the conversion to HRF. (A, B) CFP, (C, D) OCT, (E, F) FAF SSC, (G, H) FAF LSC, (I, J) FLIO SSC, and (K, L) FLIO LSC of a 74-year-old patient at baseline (left column: A, C, E, G, I, and K) and 35 months follow-up (right column: B, D, F, H, J, and L). The white arrowhead indicates a hyperpigmentation with short FAF lifetime atop a druse. At follow-up, the druse was resorbed (no PED) and RPE changed to long FAF lifetime upon conversion to HRF. It shows spatial heterogeneity in the changing of lifetimes.

FIGURE 4. Different lifetimes are found in activated and migrated RPE as well as outer retinal atrophy and cRORA. (A, B) CFP, (C, D) OCT, (E, F) FAF SSC, (G, H) FAF LSC, (I, J) FLIO SSC, and (K, L) FLIO LSC of a 69-year-old patient at baseline (left column: A, C, E, G, I, and K) and 21 months (right column: B, D, F, H, J, and L) follow-up. Activated RPE atop PED (white arrowheads) shows short FAF lifetime, however, also transition to long lifetime is seen (red arrowheads). Furthermore, migrated RPE (black arrowhead), outer retinal atrophy (purple arrowhead), and cRORA (blue arrowhead) are seen.
found on PED (red arrowhead). Furthermore, HRF (black arrowhead), outer retinal atrophy (purple arrowhead), and cRORA (blue arrowhead) are seen.

The average FAF lifetimes and ESIR, found for thickened RPE, hyperpigmentation, and HRF, are given in Table 2 and shown as boxplots in Fig. 5. HRFs have significantly longer lifetimes in both spectral channels and emit at shorter wavelengths (higher ESIR) than their respective environments. For hyperpigmentation, we found longer lifetimes in LSC only. Thickened RPE atop PED exhibited significantly shorter lifetimes than in the vicinity of these lesions in SSC. A comparison of the lesion types showed significantly longer FAF lifetimes for the hyperpigmentation and HRF than for thickened RPE (both spectral channels P < 0.001). They were significantly longer for HRF than for hyperpigmentation in LSC (P < 0.001); in SSC the difference was nonsignificant (P = 0.374). The ESIR significantly increased from thickened RPE to hyperpigmentation to HRF, and the mean values were significantly different for all groups (P ≤ 0.007). No correlation was found between the change of FAF lifetimes or ESIR of any lesion type and the time to follow-up.

### Discussion

RPE dysmophia suggestive of pathologic activation is a key symptom of AMD. Hyperpigmentation and HRF are known indicators for the risk of AMD progression to cRORA in CFP and OCT, respectively. Shedding cells drop granule aggregates into the underlying BLamD. Subducted cells containing RPE organelles are found between the RPE-BL and the inner collagenous layer of Bruch’s membrane, and acquired vitelliform lesions may result from the expulsion of organelles. Some of these alterations can be seen in CFP as hyper- or hypopigmentation due to modulation of light absorptive melanin and RPE thickening in OCT. Clinicopathologic correlation revealed that in non-neovascular AMD HRF represent single and clustered RPE cells that detached from their BL and migrated into the retina.

The principal result of our study is the finding of a transition from short to long lifetimes, along with a hypochromic shift of the emission spectrum, in the compromised RPE. Whereas hyperpigmentation shows longer lifetimes than its environment only in LSC, a switch to long lifetimes in both channels is seen after cells activate and detach from the RPE layer and migrate beyond the ellipsoid zone. We could not completely elucidate at which point in the transition of the RPE cells from activation to atrophy this switch happens. Figures 2 to 4 indicate a gradual change of lifetimes not only for cells sloughed into the subretinal space, but also for in-layer cells still attached to Bruch’s membrane. Whether these cells were dissociated and what role BLamD plays if any remains to be determined by techniques providing higher resolution.

Furthermore, it is not clear yet whether the focal prolongation of lifetimes at hyperpigmentation and HRF is associated to a general prolongation of lifetimes in patients with AMD in an annulus corresponding to the outer ring of the Early Treatment of Diabetic Retinopathy Study grid (inner diameter 3 mm and outer diameter 6 mm, centered on the fovea). Hyperpigmentation as well as HRF were associated with hyper-FAF. This could be explained by the fact that a monocellular RPE layer has been replaced by stacking or clumping of cells. However, the prolongation of FAF lifetimes as well as the shift of the emission spectrum also indicate a change in fluorophore composition or intracellular environment. An alternative explanation of the hyperautofluorescence of hyperpigmentation and HRF with long lifetimes would be fluorescence from collagen IV accumulated in BLamD. However, HRF represent RPE cells migrated off their BL and the long lifetimes seem to be restricted to the spots of HRF. Thus, collagen IV in BLamD has to be questioned as a source of this particular long lifetime fluorescence.

In agreement with Sauer et al., thickened RPE atop drusenoid PED showed increased FAF intensity with shortened lifetime in SSC. Although it can be questioned whether a statistically significant 5 ps shortening of FAF lifetime has a biological relevance, this might have various explanations. First, if fluorophore composition is altered as well, the alteration differs from that in hyperpigmentation and HRF. Second, we might see fluorophores other than those in lipofuscin and melanolipofuscin, as their emission maximum is in the LSC, but FAF lifetime shortening is seen in SSC. Third, the additional fluorescence could originate from the drusenoid PED and not from the RPE. This, however, is questionable as hyperfluorescent drusen tend to have longer lifetimes. This was more clearly seen for drusen in areas of GA (i.e. not covered by RPE) as well as in histopathology.

Taken together, FLIO, in combination with other imaging modalities, suggests the following natural history of disease progression from PED to atrophy. First, RPE cells were thickened and hyperfluorescent. In this state, we see a growth of the PED, indicating a higher rate of basal deposition of material by the cells or an increased resistance for clearance through Bruch’s membrane and choriocapillaris or

### Table 2. RPE Lesions at Baseline

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Mean Difference</th>
<th>P For Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thickened RPE-BL band</td>
<td></td>
<td></td>
</tr>
<tr>
<td>μm SSC</td>
<td>256 ± 49 ps</td>
<td>261 ± 56 ps</td>
</tr>
<tr>
<td>μm LSC</td>
<td>336 ± 35 ps</td>
<td>338 ± 34 ps</td>
</tr>
<tr>
<td>ESIR</td>
<td>0.552 ± 0.079</td>
<td>0.547 ± 0.088</td>
</tr>
<tr>
<td>Hyperpigmentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>μm SSC</td>
<td>317 ± 68 ps</td>
<td>310 ± 69 ps</td>
</tr>
<tr>
<td>μm LSC</td>
<td>377 ± 56 ps</td>
<td>365 ± 50 ps</td>
</tr>
<tr>
<td>ESIR</td>
<td>0.609 ± 0.081</td>
<td>0.600 ± 0.080</td>
</tr>
<tr>
<td>HRF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>μm SSC</td>
<td>337 ± 79 ps</td>
<td>324 ± 87 ps</td>
</tr>
<tr>
<td>μm LSC</td>
<td>414 ± 50 ps</td>
<td>389 ± 46 ps</td>
</tr>
<tr>
<td>ESIR</td>
<td>0.654 ± 0.075</td>
<td>0.643 ± 0.072</td>
</tr>
</tbody>
</table>

FAF lifetimes and ESIR (mean ± standard deviation) of RPE lesions at the lesion and in its vicinity, as well as the mean of individual differences (lesion – vicinity) of these measures with P values from paired t-test.
FIGURE 5. FAF lifetimes and ESIR. Boxplots of FAF lifetimes (top: SSC, middle: LSC) and ESIR (bottom) for activated RPE, hyperpigmentations, and migrated RPE. The $P$ values are from post hoc Bonferroni test after ANOVA.
both. Subsequently, hyperpigmentation is observed, which was often found to be associated to RPE cells sloughing from the layer and migration of the cells into the retina in histology.6,8,10,48,49 A switch of fluorescence properties, linking FAF to known progression indicators associated with soft drusen. Whereas initial activation of cells atrophied PED is associated with a shortening of FAF lifetimes in SSC, a switch to long lifetimes was seen after cells sloughed from the intact layer or migrated anteriorly. Thus, FLO might be used as an early indicator of RPE changes finally leading to atrophy. It should be used in conjunction with OCT to determine the status of RPE health and can be used to study eye-tracked cellular changes that might indicate a risk for AMD progression.

Acknowledgments

Supported by National Institutes of Health (NIH) Grant 1R01EY027948.

Disclosure: M. Hammer, None; J. Jakob-Girbig, None; L. Schwanengel, None; C.A. Curcio, None; S. Hasan, None; D. Meller, None; R. Schultz, None

References


69. Lad EM, Cousins SW, Van Arnum JS, Proia AD. Abundance of infiltrating CD163+ cells in the retina of postmortem eyes.
with dry and neovascular age-related macular degeneration. 


